SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

SAN

73.96

+1.25%↑

ARGX

691.6

+0.03%↑

SHL.DE

33.51

-1.93%↓

FRE

38.8

-0.33%↓

PHIA

21.75

-1.27%↓

Home・Aandelen Lijst・Galapagos NV
Search

Galapagos NV

Gesloten

SectorGezondheidszorg

23.52 -0.84

Sell

Prijsupdate 15 mei 2026, 07:43 UTC

BuySell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

23.32

Max

23.62

Belangrijke statistieken

By Trading Economics

Inkomsten

-769M

14M

Verkoop

-894M

6.5M

K/W

Sectorgemiddelde

3.182

51.415

EPS

11.9

Winstmarge

214.257

Werknemers

704

EBITDA

-813M

-65M

Aanbevelingen

By TipRanks

Aanbevelingen

Sell

12 Maanden Prognose

+7.35% upside

Dividenden

By Dow Jones

Volgende Winsten

10 aug 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-41M

1.6B

Vorige openingsprijs

24.36

Vorige sluitingsprijs

23.52

Nieuwssentiment

By Acuity

40%

60%

127 / 345 Rangschikking in Healthcare

Galapagos NV Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

23 mrt 2026, 23:47 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

DJ

Lezen

23 mrt 2026, 22:55 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

DJ

Lezen

24 mrt 2026, 18:00 UTC

Acquisities, Fusies, Overnames

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

Lezen

24 mrt 2026, 14:25 UTC

Acquisities, Fusies, Overnames

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

Lezen

24 mrt 2026, 13:35 UTC

Acquisities, Fusies, Overnames

Gilead to Buy Ouro Medicines for $2.2 Billion. Why the Deal Is Key to Future Stock Gains. -- Barrons.com

DJ

Lezen

24 mrt 2026, 12:03 UTC

Acquisities, Fusies, Overnames

Gilead to Buy Ouro Medicines for $2.2 Billion. 'Immune Reset' Is Key to Future Gains. -- Barrons.com

DJ

Lezen

23 mrt 2026, 22:40 UTC

Acquisities, Fusies, Overnames

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

DJ

Lezen

23 mrt 2026, 22:22 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

DJ

Lezen

23 mrt 2026, 22:21 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

DJ

Lezen

23 mrt 2026, 22:20 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

DJ

Lezen

23 mrt 2026, 22:19 UTC

Acquisities, Fusies, Overnames

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

DJ

Lezen

Peer Vergelijking

Prijswijziging

Galapagos NV Prognose

Koersdoel

By TipRanks

7.35% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 25.85 EUR  7.35%

Hoogste 30 EUR

Laagste 22 EUR

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Galapagos NV - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Sell

4 ratings

0

Buy

2

Hold

2

Sell

Gebaseerd op 4 analisten die aandelenratings hebben gegeven aan Galapagos NV - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

127 / 345 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Galapagos NV

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

Andere aandelen uit de sector

SAN

Sanofi SA

73.96

↑ +1.25%

ARGX

Argenx SE

691.6

↑ +0.03%

SHL.DE

Siemens Healthineers AG

33.51

↓-1.93%

FRE

Fresenius SE & Co KGaA

38.8

↓-0.33%

PHIA

Koninklijke Philips NV

21.75

↓-1.27%
help-icon Live chat